Canis ISSN: 2398-2942

Procarbazine

Synonym(s): Procarbazine hydrochloride

Contributor(s): Prof. Susan Cotter

Introduction

Name

  • Matulane, Sigma-Tau Pharmaceuticals.

Class of drug

  • Procarbazine hydrochloride is a hydrazine derivative.
  • It acts as an alkylating agent.

Description

Molecular weight

  • 257.76 kilodaltons.

Physical properties

  • White to pale yellow crystalline powder soluble but unstable in water or aqueous solutions.
  • Only available in 50 mg capsule.

Storage requirements

  • Procedures for proper handling and storage of chemotherapy drugs should be followed.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • In humans used in combination with other anticancer drugs (MOPP) for treatment of Hodgkin's disease.
  • In dogs used in combination with other anticancer drugs for treatment of lymphoma and part of the MOPP protocol. This protocol includes mechlorethamine (nitrogen mustard) (M) combined with vincristine (O) Vincristine and prednisone (P) Prednisolone.
  • No information is available on the use of procarbazine used as a single agent in dogs.
  • The MOPP protocol is used primarily for treatment of relapsed canine lymphoma Lymphoma.
  • Not FDA-approved for use in dogs.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmacokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Caution is advised when procarbazine is combined with other myelosuppressive drugs.

with diagnostic tests

  • Not applicable.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Rassnick K M, Mauldin G E, Al-Sarraf R, Mauldin N, Moore A S & Mooney S C (2002)MOPP chemotherapy for treatment of resistant lymphoma in dogs: A retrospective study of 117 cases (1989-2000).J Vet Internal Med.16, 576-580.PubMed

Other sources of information

  • Rosenberg M, Matus R:The use of MOPP as a rescue agent for dogs with lymphoma[Abst.]Proc 11th Annual Conference of the Vet. Cancer Soc56, 1991.
  • Ogilvie GK, Moore AS:Managing the Veterinary Cancer Patient, Vet Learning Systems, Trenton, 1995, pp 248-249.
  • Physicians' Desk Reference2002, pp 3246-3247. (For some human information).

ADDED